KALARIS THERAPEUTICS INC (KLRS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.90-1.02%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KLRS
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress TH103 through ongoing Phase 1b/2 trials and initiate Phase 3 clinical trials by year-end 2027.
Stated as a priority in 2 of last 2 quarters. Management reports ongoing patient dosing in Phase 1b/2 trials and confirms Phase 3 clinical trials remain on track for initiation by year-end 2027. The trajectory is delivering as the Phase 1b/2 study progresses with preliminary data expected in 1H 2027.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Potential Phase 3 clinical trials remain on track for initiation by year-end 2027.”
“Planned Phase 3 clinical trials remain on track for 2027 year-end initiation.”
Ensure sufficient cash, cash equivalents and marketable securities to fund operations into late 2027.
Stated as a priority in 2 of last 2 quarters. Cash, cash equivalents and marketable securities decreased from $104.9 million in 2026-Q1 to $93.5 million in 2026-Q2 but remain sufficient to fund operations into Q4 2027. Management is maintaining financial stability through cash management, delivering on stated funding runway.
“$93.5 million in cash expected to fund operations into the fourth quarter of 2027.”
“$104.9 million in cash expected to fund operations into the fourth quarter of 2027.”
Complete patient dosing in Phase 1b/2 study and report preliminary data in first half of 2027.
Stated as a priority in 2 of last 2 quarters. Management expects preliminary Phase 1b/2 clinical data for TH103 in the first half of 2027. The ongoing patient dosing and trial progress align with this timeline, indicating delivery on this clinical data reporting priority.
“Preliminary data anticipated in 1H 2027 from Phase 1b/2 study of TH103.”
“Preliminary data from the Phase 1b/2 study is expected in the first half of 2027.”
Complete new manufacturing batches with process improvements to reduce impurities and support clinical trials.
Stated as a priority in 2 of last 2 quarters. Management reports successful completion of new manufacturing batches with process improvements reducing impurities. This supports clinical trial supply and indicates delivery on manufacturing enhancement goals.
“New manufacturing batch completed including process enhancements reducing impurities.”
“New manufacturing batch completed including process enhancements that have further reduced impurities.”
Appoint experienced executives including new CFO and Board member to support growth.
Newly stated in 2026-Q2. Management announced appointment of Liisa Bayko as CFO and Laurie Keating to the Board. This priority is recent and shows progress in strengthening leadership to support company growth.
“Kalaris expanded leadership with hire of Liisa Bayko as CFO and Laurie Keating to Board.”
Over the trailing year it converted 0.85x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
15 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.